EquitySector - HealthcareVery High Risk
Direct
NAV (17-Jan-25)
Returns (Since Inception)
Fund Size
₹890 Cr
Expense Ratio
0.93%
ISIN
INF209KB1O25
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
11 Jul 2019
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+25.74%
+30.47% (Cat Avg.)
3 Years
+18.05%
+18.36% (Cat Avg.)
5 Years
+24.12%
+25.79% (Cat Avg.)
Since Inception
+24.04%
— (Cat Avg.)
Equity | ₹859.3 Cr | 96.51% |
Others | ₹31.03 Cr | 3.49% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹129.45 Cr | 14.54% |
Cipla Ltd | Equity | ₹76.77 Cr | 8.62% |
Torrent Pharmaceuticals Ltd | Equity | ₹72.14 Cr | 8.10% |
Apollo Hospitals Enterprise Ltd | Equity | ₹53.95 Cr | 6.06% |
Lupin Ltd | Equity | ₹46.22 Cr | 5.19% |
Aurobindo Pharma Ltd | Equity | ₹45.54 Cr | 5.12% |
Fortis Healthcare Ltd | Equity | ₹37.98 Cr | 4.27% |
Ajanta Pharma Ltd | Equity | ₹37.92 Cr | 4.26% |
Ipca Laboratories Ltd | Equity | ₹37.33 Cr | 4.19% |
Clearing Corporation Of India Limited | Cash - Repurchase Agreement | ₹32.21 Cr | 3.62% |
Alkem Laboratories Ltd | Equity | ₹28.04 Cr | 3.15% |
Alembic Pharmaceuticals Ltd | Equity | ₹25.62 Cr | 2.88% |
Abbott India Ltd | Equity | ₹23.78 Cr | 2.67% |
Vijaya Diagnostic Centre Ltd | Equity | ₹23.36 Cr | 2.62% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹22.67 Cr | 2.55% |
Dr Reddy's Laboratories Ltd | Equity | ₹22.07 Cr | 2.48% |
Mankind Pharma Ltd | Equity | ₹22.06 Cr | 2.48% |
Jupiter Life Line Hospitals Ltd | Equity | ₹20.54 Cr | 2.31% |
Sai Life Sciences Ltd | Equity | ₹19.15 Cr | 2.15% |
Emcure Pharmaceuticals Ltd | Equity | ₹17.67 Cr | 1.98% |
Gland Pharma Ltd | Equity | ₹16.78 Cr | 1.88% |
Medi Assist Healthcare Services Ltd | Equity | ₹15.08 Cr | 1.69% |
Onesource Speciality Pharma Ltd | Equity | ₹11.42 Cr | 1.28% |
Akums Drugs and Pharmaceuticals Ltd | Equity | ₹11.02 Cr | 1.24% |
Zydus Lifesciences Ltd | Equity | ₹10.67 Cr | 1.20% |
Procter & Gamble Health Ltd | Equity | ₹9.95 Cr | 1.12% |
Suraksha Diagnostic Ltd | Equity | ₹8.35 Cr | 0.94% |
Vinati Organics Ltd | Equity | ₹7.03 Cr | 0.79% |
Sanofi India Ltd | Equity | ₹6.77 Cr | 0.76% |
Net Receivables / (Payables) | Cash | ₹-1.18 Cr | 0.13% |
Large Cap Stocks
43.48%
Mid Cap Stocks
30.73%
Small Cap Stocks
14.71%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹840.85 Cr | 94.44% |
Basic Materials | ₹7.03 Cr | 0.79% |
Standard Deviation
This fund
16.10%
Cat. avg.
15.72%
Lower the better
Sharpe Ratio
This fund
0.81
Cat. avg.
0.87
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.61
Higher the better
Since July 2019
Since November 2022
ISIN INF209KB1O25 | Expense Ratio 0.93% | Exit Load 1.00% | Fund Size ₹890 Cr | Age 5 years 6 months | Lumpsum Minimum ₹1,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹31.91 Cr | 32.1% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 0.9% | 1.0% | ₹890.33 Cr | 25.7% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹890.33 Cr | 24.0% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹44.16 Cr | 30.6% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹230.79 Cr | 32.2% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹230.79 Cr | 29.8% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2863.52 Cr | 31.1% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2863.52 Cr | 29.2% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹922.81 Cr | 29.1% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹20.52 Cr | 29.7% |
Total AUM
₹3,79,726 Cr
Address
One World Centre, Tower 1, 17th Floor, Mumbai, 400 013
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Direct
NAV (17-Jan-25)
Returns (Since Inception)
Fund Size
₹890 Cr
Expense Ratio
0.93%
ISIN
INF209KB1O25
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
11 Jul 2019
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+25.74%
+30.47% (Cat Avg.)
3 Years
+18.05%
+18.36% (Cat Avg.)
5 Years
+24.12%
+25.79% (Cat Avg.)
Since Inception
+24.04%
— (Cat Avg.)
Equity | ₹859.3 Cr | 96.51% |
Others | ₹31.03 Cr | 3.49% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹129.45 Cr | 14.54% |
Cipla Ltd | Equity | ₹76.77 Cr | 8.62% |
Torrent Pharmaceuticals Ltd | Equity | ₹72.14 Cr | 8.10% |
Apollo Hospitals Enterprise Ltd | Equity | ₹53.95 Cr | 6.06% |
Lupin Ltd | Equity | ₹46.22 Cr | 5.19% |
Aurobindo Pharma Ltd | Equity | ₹45.54 Cr | 5.12% |
Fortis Healthcare Ltd | Equity | ₹37.98 Cr | 4.27% |
Ajanta Pharma Ltd | Equity | ₹37.92 Cr | 4.26% |
Ipca Laboratories Ltd | Equity | ₹37.33 Cr | 4.19% |
Clearing Corporation Of India Limited | Cash - Repurchase Agreement | ₹32.21 Cr | 3.62% |
Alkem Laboratories Ltd | Equity | ₹28.04 Cr | 3.15% |
Alembic Pharmaceuticals Ltd | Equity | ₹25.62 Cr | 2.88% |
Abbott India Ltd | Equity | ₹23.78 Cr | 2.67% |
Vijaya Diagnostic Centre Ltd | Equity | ₹23.36 Cr | 2.62% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹22.67 Cr | 2.55% |
Dr Reddy's Laboratories Ltd | Equity | ₹22.07 Cr | 2.48% |
Mankind Pharma Ltd | Equity | ₹22.06 Cr | 2.48% |
Jupiter Life Line Hospitals Ltd | Equity | ₹20.54 Cr | 2.31% |
Sai Life Sciences Ltd | Equity | ₹19.15 Cr | 2.15% |
Emcure Pharmaceuticals Ltd | Equity | ₹17.67 Cr | 1.98% |
Gland Pharma Ltd | Equity | ₹16.78 Cr | 1.88% |
Medi Assist Healthcare Services Ltd | Equity | ₹15.08 Cr | 1.69% |
Onesource Speciality Pharma Ltd | Equity | ₹11.42 Cr | 1.28% |
Akums Drugs and Pharmaceuticals Ltd | Equity | ₹11.02 Cr | 1.24% |
Zydus Lifesciences Ltd | Equity | ₹10.67 Cr | 1.20% |
Procter & Gamble Health Ltd | Equity | ₹9.95 Cr | 1.12% |
Suraksha Diagnostic Ltd | Equity | ₹8.35 Cr | 0.94% |
Vinati Organics Ltd | Equity | ₹7.03 Cr | 0.79% |
Sanofi India Ltd | Equity | ₹6.77 Cr | 0.76% |
Net Receivables / (Payables) | Cash | ₹-1.18 Cr | 0.13% |
Large Cap Stocks
43.48%
Mid Cap Stocks
30.73%
Small Cap Stocks
14.71%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹840.85 Cr | 94.44% |
Basic Materials | ₹7.03 Cr | 0.79% |
Standard Deviation
This fund
16.10%
Cat. avg.
15.72%
Lower the better
Sharpe Ratio
This fund
0.81
Cat. avg.
0.87
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.61
Higher the better
Since July 2019
Since November 2022
ISIN INF209KB1O25 | Expense Ratio 0.93% | Exit Load 1.00% | Fund Size ₹890 Cr | Age 5 years 6 months | Lumpsum Minimum ₹1,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹31.91 Cr | 32.1% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 0.9% | 1.0% | ₹890.33 Cr | 25.7% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹890.33 Cr | 24.0% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹44.16 Cr | 30.6% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹230.79 Cr | 32.2% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹230.79 Cr | 29.8% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2863.52 Cr | 31.1% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2863.52 Cr | 29.2% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹922.81 Cr | 29.1% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹20.52 Cr | 29.7% |
Total AUM
₹3,79,726 Cr
Address
One World Centre, Tower 1, 17th Floor, Mumbai, 400 013
Get your portfolio reviewed by experts